Past the patent cliff, pharmas are set for rebound in NMEs, says IMS
July 12 2012
Industry pipelines might not be brimful of blockbusters, but after years of meager output, biopharma firms are poised to tap ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.